Hints and tips:
Related Special Reports
...GIC took a 25 per cent stake in CitizenM five years ago in a deal that valued the business at €2bn including debt....
...However, the broadcaster walked away from the talks this summer, with people close to the situation citing a reluctance among its investors to back such a large asking price....
...A sharper focus on operations is a crucial part of efforts by activist investors to put the gambling group in a position where it could ultimately be sold or broken up....
...A Gambling Commission spokesperson said the regulator ran a “fair and robust competition” for the lottery contract....
...Jyotin Sethi, a former private equity executive, led the funding round, with help from Tamweel Capital, a London-based boutique advisory firm which advises on small M&A deals....
...the sale if a buyer is found....
...A small number of people in equities are trialling a rival offering from US data and software company FactSet, which costs about a third of the price, one of the people said....
...as a “very quiet and private person with a deep intellect”....
...But a handful of European shipbuilders have a competitive edge in niche markets such as cruise ship construction....
...“It’s a huge potential clinical breakthrough and so I do think [sales growth is] going to be material”....
...He has added close to 60 shops since taking over Barnes & Noble in 2019, and said that “they are all a success . . . people queue up on the opening day....
...Eli Lilly’s tirzepatide drug had less than 10 per cent absolute weight reduction at all doses after its late-stage trial, noted Thomas Smith, an analyst at Leerink Partners....
...Greencore did complete a £50mn share repurchase programme recently, but a person familiar with Oasis’s thinking described them as “really small”....
...It then established an outpost in 2014 in a cluster of renovated farm buildings in the rural English town of Bruton. The launch was a boon to property prices across the local Somerset area....
...A decision on Eli Lilly’s donanemab drug from the US Food and Drug Administration was originally due by the end of the first quarter, but the medicine will now be subject to a further review by an advisory...
...’s chief medical officer, said in a statement....
...A deal combining Choice and its bigger rival, both of which operate under a franchised model, would have created one of the largest budget hotel owners in the US, with nearly 1.5mn rooms....
...Orchard cited a review by the Institute for Clinical and Economic Review (ICER), a US non-profit that attempts to calculate a fair price for drugs, which concluded last year that Lenmeldy would be cost-effective...
...A decision from the US Food and Drug Administration on Eli Lilly’s donanemab drug was originally due by the end of the first quarter but the breakthrough medicine will now be subject to a further review...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
...In a regulatory filing, Soho House said that it “fundamentally rejects” the report, which accused the members club group of being “a company with a broken business model and terrible accounting”....
...in 1995, of being “a company with a broken business model and terrible accounting”....
...Pulling off a business revival, whether it is pivoting to a new opportunity (generally as a core market fades) or resurrecting a business from a scandal or mishap, is difficult stuff — full of ambitious...
...Medicare Part D drug benefit plans, which provide coverage for more than 50mn Americans, can cover anti-obesity medications that receive regulatory approval for a separate medical problem, according to new...
...products and uncertainty around a potential menthol ban in the US”....
International Edition